Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers.
The effect of atropine, glycopyrrolate, metoclopramide and cisapride on the antral motility was investigated in eight dogs (four Beagles and four Labradors) using passive telemetry. Both anticholinergics induced a pronounced and lasting reduction of the intensity and frequency of the contractions. A definite dose-related inhibition of the antral motility was seen in Beagles, similar for both active substances. Low doses of atropine (0.02 mg/kg BW i.m.) and glycopyrrolate (0.005 mg/kg BW i.m.) completely inhibited the gastric motility for at least 30 min, whereas higher doses (0.04 or 0.01 mg/kg BW) caused a cessation of activity for more than 3 h. In Labradors, the effects of both active substances were not so dose related and the effect of glycopyrrolate lasted at least 6 h, whereas the effect of atropine gradually decreased after 3 h. A distinct breed difference regarding the effect of the two prokinetics on the antral motility was also observed. In Beagles, the prokinetics, at a low dose (metoclopramide 0.3 mg/kg BW, cisapride 0.2 mg/kg BW), resulted in a significant increase in the amplitude integral. Higher doses (metoclopramide 0.6 mg/kg BW, cisapride 0.5 mg/kg BW) also increased the integrals of the pressure profiles, but significantly less than with the lower doses. In Labradors, both medications, mainly at higher doses, resulted in an increase of the contraction amplitudes. The low dose had no (cisapride) or only a transient effect (metoclopramide). The frequency of the antral contractions was not at all influenced by cisapride, and only in Beagles metoclopramide resulted in a dose-related increase. It is not clear if the different results in Labradors and Beagles are because of breed or body weight.
Burger
D M
DM
Department of Reproduction, Vetsuisse-Faculty, University of Zurich, CH-8057 Zurich, Switzerland.
Wiestner
T
T
Hubler
M
M
Binder
H
H
Keiser
M
M
Arnold
S
S
D000818:Animals; D001285:Atropine / Q000008:administration & dosage / Q000493:pharmacokinetics; D001835:Body Weight / Q000502:physiology; D001947:Breeding; D020117:Cisapride / Q000008:administration & dosage / Q000493:pharmacokinetics; D004285:Dogs / Q000378:metabolism* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004576:Electromyography / Q000379:methods / Q000662:veterinary; D005746:Gastric Emptying / Q000187:drug effects* / Q000502:physiology; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000493:pharmacokinetics; D008787:Metoclopramide / Q000008:administration & dosage / Q000493:pharmacokinetics; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics*
D005765:Gastrointestinal Agents; D018727:Muscarinic Antagonists; D001285:Atropine; D008787:Metoclopramide; D020117:Cisapride; D006024:Glycopyrrolate